Ten years of anti-vascular endothelial growth factor therapy

Over the past 10 years, targeting vascular endothelial growth factor A (VEGFA) has been widely pursued in the treatment of various cancers and ophthalmic diseases. Here, Ferrara and Adamis provide an overview of the discovery of VEGFA and the development of anti-VEGFA therapies, addressing key challenges and issues that remain in the application of these agents. The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator...